» Articles » PMID: 26862232

Costs of Expanded Rapid HIV Testing in Four Emergency Departments

Overview
Publisher Sage Publications
Specialty Public Health
Date 2016 Feb 11
PMID 26862232
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The HIV Prevention Trials Network (HPTN) 065 trial sought to expand HIV screening of emergency department (ED) patients in Bronx, New York, and Washington, D.C. This study assessed the testing costs associated with different expansion processes and compared them with costs of a hypothetical optimized process.

Methods: Micro-costing studies were conducted in two participating EDs in each city that switched from point-of-care (POC) to rapid-result laboratory testing. In three EDs, laboratory HIV testing was only conducted for patients having blood drawn for clinical reasons; in the other ED, all HIV testing was conducted with laboratory testing. Costs were estimated through direct observation and interviews to document process flows, time estimates, and labor and materials costs. A hypothetical optimized process flow used minimum time estimates for each process step. National wage and fringe rates and local reagent costs were used to determine the average cost (excluding overhead) per completed nonreactive and reactive test in 2013 U.S. dollars.

Results: Laboratory HIV testing costs in the EDs ranged from $17.00 to $23.83 per completed nonreactive test, and POC testing costs ranged from $17.64 to $37.60; cost per completed reactive test ranged from $89.29 to $123.17. Costs of hypothetical optimized HIV testing with automated process steps were approximately 45% lower for nonreactive tests and 20% lower for reactive tests. The cost per ED visit to conduct expanded HIV testing in each hospital ranged from $1.21 to $3.96.

Conclusion: An optimized process could achieve additional cost savings but would require an investment in electronic system interfaces to further automate testing processes.

Citing Articles

Economic Evaluation of Delivering an Evidence-Based Online HIV Prevention Program to MSM via Direct-To-Consumer Marketing Versus Community-Based Organization Recruitment.

Munroe S, Schackman B, Madkins K, Saber R, Macapagal K, Vititow J J Acquir Immune Defic Syndr. 2024; 98(3):257-264.

PMID: 39621530 PMC: 11866060. DOI: 10.1097/QAI.0000000000003572.


Analyzing the Costs and Impact of the TakeMeHome Program, a Public-Private Partnership to Deliver HIV Self-Test Kits in the United States.

Shrestha R, Hecht J, Chesson H J Acquir Immune Defic Syndr. 2023; 95(2):144-150.

PMID: 37831623 PMC: 10841436. DOI: 10.1097/QAI.0000000000003323.


Financing Benefits and Barriers to Routine HIV Screening in Clinical Settings in the United States: A Scoping Review.

Serag H, Clark I, Naig C, Lakey D, Tiruneh Y Int J Environ Res Public Health. 2023; 20(1).

PMID: 36612775 PMC: 9819288. DOI: 10.3390/ijerph20010457.


Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.

Neilan A, Landovitz R, Le M, Grinsztejn B, Freedberg K, McCauley M Ann Intern Med. 2022; 175(4):479-489.

PMID: 35099992 PMC: 9087297. DOI: 10.7326/M21-1548.


Cost-Effectiveness Analysis in Implementation Science: a Research Agenda and Call for Wider Application.

Krebs E, Nosyk B Curr HIV/AIDS Rep. 2021; 18(3):176-185.

PMID: 33743138 PMC: 7980756. DOI: 10.1007/s11904-021-00550-5.


References
1.
Rizza S, MacGowan R, Purcell D, Branson B, Temesgen Z . HIV screening in the health care setting: status, barriers, and potential solutions. Mayo Clin Proc. 2012; 87(9):915-24. PMC: 3538498. DOI: 10.1016/j.mayocp.2012.06.021. View

2.
Brooks L, Rietmeijer C, McEwen D, Subiadur J, Mettenbrink C . Normalizing HIV testing in a busy urban sexually transmitted infections clinic. Sex Transm Dis. 2009; 36(3):127-8. DOI: 10.1097/OLQ.0b013e318191701c. View

3.
Dowdy D, Rodriguez R, Hare C, Kaplan B . Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department. Acad Emerg Med. 2011; 18(7):745-53. DOI: 10.1111/j.1553-2712.2011.01110.x. View

4.
Shirreffs A, Lee D, Henry J, Golden M, Stekler J . Understanding barriers to routine HIV screening: knowledge, attitudes, and practices of healthcare providers in King County, Washington. PLoS One. 2012; 7(9):e44417. PMC: 3435280. DOI: 10.1371/journal.pone.0044417. View

5.
Schackman B, Metsch L, Colfax G, Leff J, Wong A, Scott C . The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2012; 128(1-2):90-7. PMC: 3546145. DOI: 10.1016/j.drugalcdep.2012.08.009. View